Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Gautam Borthakur, Srdan Verstovsek, C. Cameron Yin, Keyur P. Patel, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2024-211674

Published: 2024

Journal Articles

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, C. Cameron Yin, Christopher D. Pacheco, Christopher P. Ly, Enes Dasdemir, Evan N. Cohen, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Hagop M. Kantarjian, Zeev Estrov, Patrick K. Reville, Andrew Dunbar, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2024-211966

Published: 2024

Journal Articles

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, Christopher D. Pacheco, C. Cameron Yin, Ying Zhang, Ping Li, Evan N. Cohen, Javier A. Gomez, Jared K. Burks, Srdan Verstovsek, Zeev Estrov

Blood (2023) 142 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2023-191024

Published: 2023

Journal Articles

TET2-Mediated Dysregulation of Heterochromatin in Age-Related Clonal Hematopoiesis

Tingting Hong, Jia Li, Lei Guo, Maryn Cavalier, Tianlu Wang, Shaohai Fang, Anna Guzman, Katharina Wohlan, Chiraag Kapadia, Yaling Yang, C. Cameron Yin, Shaoying Li, M. James You, Xiaodong Cheng, Yubin Zhou, Margaret Goodell, Yun Nancy Huang

Blood (2023) 142 (Supplement 1): 5606.

https://doi.org/10.1182/blood-2023-178792

Published: 2023

Journal Articles

Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Blood (2022) 140 (Supplement 1): 6378–6380.

https://doi.org/10.1182/blood-2022-165616

Published: 2022

Journal Articles

Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome

Blood (2022) 140 (Supplement 1): 3559–3561.

https://doi.org/10.1182/blood-2022-169476

Published: 2022

Journal Articles

Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3598–3600.

https://doi.org/10.1182/blood-2022-162806

Published: 2022

Journal Articles

Disease Characteristics of Multiple Myeloma Involving BRAF Mutations

Shehab Fareed Mohamed, Maliha Khan, Andres Quesada, Junsheng Ma, Pei Lin, C. Cameron Yin, Koji Sasaki, Gautam Borthakur, Naveen Pemmaraju, Qaiser Bashir, Muzaffar H. Qazilbash, Gregory P. Kaufman, Melody R. Becnel

Blood (2021) 138 (Supplement 1): 4755.

https://doi.org/10.1182/blood-2021-147400

Published: 2021

Journal Articles

ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis

Blood (2021) 138 (Supplement 1): 2403.

https://doi.org/10.1182/blood-2021-148807

Published: 2021

Journal Articles

Selective Targeting of Splicing Factor Mutant Hematopoietic Stem and Progenitor Cells Via STAT3 Inhibition

Kathryn S Potts, Rosannah C. Cameron, Noura Ghazale, Varun Gupta, Juan Martin Barajas, LaShanale Wallace, Ana Leal-Cervantes, Srinivas Aluri, Kith Pradhan, Mia McKinstry, Xiaoying Bai, Gaurav S Choudhary, Aditi Shastri, Amit Verma, Esther A. Obeng, Teresa V. Bowman

Blood (2021) 138 (Supplement 1): 1509.

https://doi.org/10.1182/blood-2021-151338

Published: 2021

Journal Articles

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Rashmi Kanagal-Shamanna, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Nicholas J. Short, MD, C. Cameron Yin, MD PhD, Keyur Patel, MD PhD, Sanam Loghavi, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Susan M. O'Brien, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-142012

Published: 2020

Journal Articles

Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-137473

Published: 2020

Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Blood (2020) 136 (Supplement 1): 45–47.

https://doi.org/10.1182/blood-2020-143401

Published: 2020

Journal Articles

Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137259

Published: 2020

Journal Articles

Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137440

Published: 2020

Journal Articles

Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137167

Published: 2020

Journal Articles

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Xiang Li, Rachel Kositsky, Anupama Reddy, PhD, Cassandra Love, Kikkeri Naresh, Jean L. Koff, MD, Ilja Nystrand, Sirpa Leppä, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Johannes Dunkel, Panu Kovanen, MD PhD, Qiu Qin, Govind Bhagat, MD, Rebecca J Leeman-Neill, MDPhD, Rashmi S. Goswami, MD PhD, Sarah Wildeman, Jan Delabie, MDPhD, Richard Burack, MD PhD, Andrew G Evans, MD PhD, Catalina Amador, MD, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, MD, Jie Xu, C. Cameron Yin, MD PhD, Anne Ortved Gang, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Jason Yongsheng Chan, MBBS, MRCP, Daryl Ming Zhe Cheah, Shin Yeu Ong, MD FRCPath, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Magdalena Czader, MD PhD, Lin Wang, PhD, Amber Landis, Michael C. Churnetski, David L. Jaye, MD, Christopher R. Flowers, MD MS, Chad M. McCall, MD PhD, Jadee Neff, MD PhD, Matthew S. McKinney, MD, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, MD, Agata M. Bogusz, MDPhD, Andrea Stafford Hintz, HSLT, Alexandra E. Kovach, MD, Nishitha Reddy, MD, Mary Ann Thompson Arildsen, MD PhD, Emily F Mason, MD PhD, Ridas Juskevicius, MD, William Choi, MBBS,MRCP, Rex Au-Yeung, Eric Tse, MBBS, PhD FRCP, FRCPath, Vincent Sarno, Amy Chadburn, MD, Rafael Lopez, MD, Jennifer R Chapman, MD, Amir Behdad, MD, Neta Goldschmidt, MD, John Goodlad, MD, Cathy Burton, Raju Pillai, MD, Abner Louissaint, Jr., MD PhD, Dina Sameh Soliman, MD MB, MMSc, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 19.

https://doi.org/10.1182/blood-2019-130255

Published: 2019

Journal Articles

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Kirill A. Lyapichev, MD, L. Jeffrey Medeiros, MD, Shaoying Li, MD, C. Cameron Yin, MD PhD, Guilin Tang, MD, M. James You, MD PhD, Sergej Konoplev, Swaminathan P. Iyer, MD, Carlos E. Bueso-Ramos, MD PhD, Roberto N. Miranda, MD, Jie Xu

Blood (2019) 134 (Supplement_1): 1560.

https://doi.org/10.1182/blood-2019-124556

Published: 2019

Journal Articles

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Blood (2019) 134 (Supplement_1): 2815.

https://doi.org/10.1182/blood-2019-126175

Published: 2019

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Srdan Verstovsek, MD PhD, Nitin Jain, MD, Madeline Duvic, MD, Phyu Aung, MD, C. Cameron Yin, MD PhD, Sergej Konoplev, Keyur P. Patel, MBBS, PhD, Sherry A. Pierce, BSN, BA, Hannah Beird, PhD, Muzaffar H. Qazilbash, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2723.

https://doi.org/10.1182/blood-2019-132185

Published: 2019

NARROW

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

TET2-Mediated Dysregulation of Heterochromatin in Age-Related Clonal Hematopoiesis

Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome

Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Disease Characteristics of Multiple Myeloma Involving BRAF Mutations

ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis

Selective Targeting of Splicing Factor Mutant Hematopoietic Stem and Progenitor Cells Via STAT3 Inhibition

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma

Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only